High Threat
2
Direct competitors, launched or near
Medium-High Threat
2
Emerging; well-funded & in trials
Companies Launched
4
LDT live or commercially available
Recent Events (90d)
5
Publications, data, funding, launches
Total Tracked Funding
$1.6B
Freenome ($1.5B) + others disclosed
Competitive Landscape
Category
Threat
| Company |
Category |
Threat |
Modality |
Launch Status |
Sensitivity |
Specificity |
Study N |
Latest Development |
No competitors match the selected filters.
Clinical Performance — All Competitors vs. Proteomics PBC INTEGRAL
⭐ Proteomics PBC INTEGRAL reference: AUC 0.885 · N=3,695 · Pre-diagnostic, prospective
Sensitivity Comparison (%)
At reported threshold. All companies with disclosed sensitivity shown. Bars absent = not yet disclosed.
Specificity Comparison (%)
All companies with disclosed specificity shown. Note: Veracyte & Biodesix are post-LDCT (different clinical stage).
Funding Landscape (Disclosed)
Total Funding ($M)
Companies with disclosed funding only. ⚠ Freenome figure ($1,500M) sourced from tracker — verify against latest disclosure.
Events Log — Recent Developments
document.getElementById('last-updated').textContent = new Date(document.lastModified).toLocaleDateString('en-GB', { day: 'numeric', month: 'short', year: 'numeric' });
